Healthcare stocks rise during market volatility

The healthcare sector has been on fire over the last several years, with investors in the space seeing big returns on stocks. Even during periods of volatility across the stock market at the end of 2018, the healthcare sector remained consistent, with “stellar returns,” Bloomberg reported.

The end of 2018 was one of only four periods when valuations swung up and down so intensely. However, the 60 publicly traded companies in the S&P 500’s Health Care Index did just fine. In fact, they were the “sole mainstay” as market winners amid all those swing periods, according to Bloomberg.

While the S&P 500, Dow Jones Industrial Average and Nasdaq faltered as much as 5 percent at the end of 2018, three of the top five U.S.-based mutual funds with assets greater than $5 billion specialized in healthcare stocks.

Unlike other sectors, the healthcare space isn’t as impacted by global economic volatility.

“Rising demand for health-related products and services, regardless of the economy’s cycle, military conflicts and political firestorms, helps explain why health-care investors can ignore Trump’s daily tweets and his tariffs on trade with Canada, China, Mexico and the EU,” Bloomberg reported.

The sector has been performing well since the Affordable Care Act, in particular.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.